PETization is Nexvet’s proprietary platform technology, which is designed to harness proprietary cDNA library data to rapidly translate monoclonal antibodies (mAbs) between species.
PETized™ mAbs are uniquely designed to be recognized as “native” by an animal’s immune system, a property we refer to as “100% species-specificity”.
This overcomes the issue mAbs from other species often face when used without modification in another species. This can induce a significant negative immune response, or “immunogenicity”, which is the body’s reaction to the identification of foreign material. This can result in a biologic therapy being inactivated and cleared from the body, thereby diminishing or removing its therapeutic effect.
Our PETization platform is a proprietary algorithmic approach that has demonstrated a reduction in the time and cost typically associated with the development of mAbs using conventional methods, such as CDR grafting and subsequent affinity maturation.
By comparison with these methods, we believe PETization, with its single computational design step, can significantly reduce the time required for laboratory work when designing new mAbs.
PETization harnesses our proprietary cDNA libraries to compare the sequences of the heavy and light chains of a parent (or ‘donor’) human or rodent mAb to a database of heavy and light chains from the target species.
By applying our algorithms, PETization is designed to determine the minimal number of changes at each position in the amino acid sequences required to convert donor mAb heavy and light chain sequences into mAb sequences containing only amino acids identified within the target species, at each position on the sequence.
The resulting “100% species-specific” mAb sequences carry a lower risk of rejection due to immunogenicity, while preserving the attraction between the mAb and its target, a property known as affinity. This maintains the function of the parent antibody in the new species.
We have used PETization to successfully convert human and rodent mAbs into canine, feline and equine mAbs, thereby leveraging their safety and efficacy profile for our companion animal therapies in development.
We believe our PETization platform offers the following important advantages over other approaches to the design, discovery and development of mAbs for the veterinary care industry:
PETization is designed to substantially reduce the time involved in the discovery process for new mAbs with high affinity when compared to conventional discovery techniques.
mAbs with higher affinity require less active pharmaceutical ingredient to achieve a therapeutic dose, leading to lower cost of goods.
Harnessing existing donor mAb manufacturing, safety and clinical efficacy data can significantly reduce costs, time-to-market and regulatory and clinical risk.
PETization enables us to rapidly identify new product candidates for many indications across multiple species.
Our proprietary cDNA library of mAb sequences allows us to use the natural variations found in mAbs to generate novel, species-specific mAbs.